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In mammals, methionine adenosyltransferase (MAT),
the enzyme responsible for S-adenosylmethionine
(AdoMet) synthesis, is encoded by two genes, MAT1A
and MAT2A. In liver, MAT1A expression is associated
with high AdoMet levels and a differentiated phenotype,
whereas MAT2A expression is associated with lower
AdoMet levels and a dedifferentiated phenotype. In the
current study, we examined regulation of MAT2A gene
expression by L-methionine availability using HepG2
cells. In L-methionine-deficient cells, MAT2A gene ex-
pression is rapidly induced, and methionine adenosyl-
transferase activity is increased. Restoration of L-methi-
onine rapidly down-regulates MAT2A mRNA levels; for
this effect, L-methionine needs to be converted into
AdoMet. This novel action of AdoMet is not mediated
through a methyl transfer reaction. MAT2A gene expres-
sion was also regulated by 5-methylthioadenosine, but
this was dependent on 5-methylthioadenosine conver-
sion to methionine through the salvage pathway. The
transcription rate of the MAT2A gene remained un-
changed during L-methionine starvation; however, its
mRNA half-life was significantly increased (from 100
min to more than 3 h). The effect of L-methionine with-
drawal on MAT2A mRNA stabilization requires both
gene transcription and protein synthesis. We conclude
that MAT2A gene expression is modulated as an adapt-
ive response of the cell to L-methionine availability
through its conversion to AdoMet.
Regulation of cellular functions by nutrients, including the
control of gene expression, is well documented in prokaryotes
and lower eukaryotes. In mammals, these responses have also
been observed, and lipids and carbohydrates, among other di-
etary constituents, have been shown to be important regulators
of gene expression (1–3). Mammalian cells can also adapt to
dietary or pathological fluctuations in amino acid availability
(4, 5). Amino acid limitation elicits a series of cellular re-
sponses, among which the up-regulation of amino acid trans-
port systems was one of the first to be recognized (reviewed in
Refs. 6 and 7). Subsequently, a number of genes have been
shown to specifically change their expression levels following
amino acid deprivation, although the underlying mechanisms
are not completely known (4, 5). Under such limiting condi-
tions, amino acids play a signaling role in the cell, conveying
regulatory messages to the transcriptional machinery and af-
fecting the turnover of specific mRNAs and proteins (5, 8).
These processes are beginning to be understood with work
carried out mainly in cultured cells, given the complexity of the
response to amino acid deprivation in intact animals, which
includes nutrient-induced changes in hormone levels.
L-Methionine is an essential amino acid required for protein
synthesis and participates, together with ATP, in the formation
of S-adenosylmethionine (AdoMet),1 the principal biological
methyl donor (9–11). Upon transfer of its activated methyl
group to many different acceptor molecules, AdoMet is con-
verted into S-adenosylhomocysteine (AdoHcy), a molecule that
can be further hydrolyzed to adenosine and homocysteine in a
reversible reaction (10). Homocysteine in turn may be con-
verted into cystathionine or remethylated back to L-methio-
nine, depending on the cellular needs for this amino acid (10).
Mammalian cells have developed a series of adaptive mecha-
nisms that respond to fluctuations in L-methionine availability,
which have been best characterized in the liver and involve the
modulation of enzymatic activities implicated in methionine
metabolism (10, 12). Some of these mechanisms, including the
capacity to remethylate homocysteine, are impaired in the
transformed cell, giving rise to the condition of “methionine
dependence” in cancer (reviewed in Ref. 13).
The first step in L-methionine metabolism, the synthesis of
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AdoMet, is catalyzed by the enzyme methionine adenosyltrans-
ferase (MAT). In mammals, there are three isoenzymes for
MAT (MAT I, MAT II, and MAT III); MAT I and MAT III are
two oligomeric forms (a tetramer and dimer, respectively) of
the protein coded by MAT1A gene, whereas MAT II is the
product of the MAT2A gene (11, 14, 15). The expression of both
genes is differentially regulated; MAT1A is expressed in the
adult hepatocyte, whereas MAT2A is expressed in all other
cells of the organism and in the fetal hepatocyte (11, 14).
Interestingly, MAT2A expression is induced when the adult
hepatocyte proliferates (as occurs during liver regeneration)
and upon neoplastic transformation of the liver, where MAT1A
expression is silenced (11, 16–18). Although both enzymes cat-
alyze the same reaction, they display distinct catalytic and
regulatory properties that impact on the intracellular concen-
trations of AdoMet (11). We have recently shown that in liver,
AdoMet plays a pivotal role in the regulation of essential cel-
lular functions, such as the control of cellular proliferation,
differentiation, and apoptosis (18–24); consequently, the levels
of this metabolite must be tightly controlled in this organ. In
the present work, we describe how expression of the MAT2A
gene is acutely regulated by the availability of L-methionine
and investigate the mechanisms behind this response. Our
observations indicate that fluctuations in L-methionine avail-
ability regulate MAT2A expression mainly at the level of
mRNA turnover; additionally, we demonstrate an essential
role for AdoMet in this response, further supporting the hy-
pothesis of AdoMet as a signaling molecule in the liver (25).
EXPERIMENTAL PROCEDURES
Chemicals—AdoMet, in the stable form of sulfate-p-toluenesulfonate
salt produced by Knoll (Milan, Italy) was from Europharma (Madrid,
Spain). 5-Methylthioadenosine (MTA) was generously provided by
Knoll (Milan, Italy). All other reagents were of analytical grade, and
unless otherwise stated, they were purchased form Sigma.
Cell Culture and Treatment Conditions—Human HepG2 hepatoma
cells were obtained from the American Type Culture Collection (ATCC)
(Manassas, VA), and HuH7 human hepatoma cells were from our tissue
culture facility at the University of Navarra. Cells were maintained in
minimum Eagle’s medium (MEM) supplemented with 10% fetal calf
serum, 2 mM glutamine, 100 units/ml penicillin, and 100 g/ml strep-
tomycin (all from Invitrogen) at 37 °C in a humid atmosphere of 5% CO2
in air. To test MAT2A expression, cells were cultured in L-methionine-
deficient MEM supplemented with 5% fetal calf serum and varying
concentrations of L-methionine (Sigma). It has been estimated that
L-methionine concentration in bovine serum is around 15 M, so the
final concentration of L-methionine in our experiments would be around
0.75 M; in this work, this is referred to as L-methionine restriction. In
some experiments, cells were kept in Krebs-Ringer bicarbonate (KRB)
and varying concentrations of L-methionine. No significant differences
in cell viability, as determined by trypan blue exclusion test, were
observed under the different treatments.
Determination of MAT Activity and AdoMet Levels—Cells (3  106)
were lysed by freeze thawing in 300 l of 10 mM Tris-HCl (pH 7.5)
containing 0.3 mM sucrose, 0.1% -mercaptoethanol, 1 mM benzami-
dine, and 0.1 mM phenylmethylsulfonyl fluoride. The homogenate was
centrifuged for 30 min at 10,000  g, and MAT activity was assayed in
the supernatant as described previously (27). For the determination of
AdoMet concentrations, cells were lysed and deproteinized in 0.4 M
perchloric acid and centrifuged at 12,000  g for 15 min at 4 °C.
Supernatants were filtered and analyzed by high performance liquid
chromatography as described previously (27).
RNA Isolation and Northern Blot Analysis—Total RNA was isolated
by the guanidinium thiocyanate method as described (28, 29). RNA
concentration was determined spectrophotometrically before use, and
the integrity was checked by electrophoresis with subsequent ethidium
bromide staining. Electrophoresis of RNA and gel blotting were carried
out as described (27, 29). Northern hybridization analysis was per-
formed on total RNA using standard procedures as described (27, 29).
All probes (human MAT2A and glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) cDNAs) were labeled with [32P]dCTP using a random
primer kit (RediPrime DNA Labeling System; Amersham Bisociences).
To ensure equal loading of RNA samples, membranes were also hybrid-
ized with 32P-labeled 18 S rRNA DNA probe. Quantitation was per-
formed by scanning densitometry of the x-ray films, using the Molecular
Analyst software (Bio-Rad), and values were normalized to 18 S rRNA.
Nuclear Run-on Transcription Assay—Nuclei from 3  107 HepG2
cells kept in MEM without L-methionine for different durations were
isolated as described previously (27). Transcription reactions were per-
formed for 30 min at 37 °C with 60 l of the isolated nuclei in a final
volume of 200 l in the presence of 100 Ci of [-32P]uridine triphos-
phate (800 Ci/mmol; Amersham Biosciences) and 0.5 mM unlabeled
nucleotides essentially as described (27). Elongated RNA transcripts
were purified by phenol extraction as described above, denatured, and
hybridized (at equivalent amounts of radioactivity (i.e. 1–2  106 cpm))
to 5 g of the corresponding cDNAs and immobilized on Nytran filters
in hybridization buffer (0.2 M NaPO4 (pH 7.2), 1 mM EDTA, 7% SDS,
45% formamide, and 250 mg/ml Escherichia coli transfer RNA as car-
rier) for 48 h at 42 °C. The DNAs used were the human MAT2A,
GAPDH, MTAP, S-adenosylhomocysteine hydrolase, and 18 S cDNAs;
pUC18 was used for background control. The filters were washed and
exposed to x-ray films. Quantitation was performed by scanning densi-
tometry of the x-ray films, using the Molecular Analyst software (Bio-
Rad). Data were normalized to the transcription of the GAPDH gene,
the steady-state mRNA levels of which were not affected by short term
L-methionine depletion.
Statistics—Unless otherwise stated, the data are means  S.E. of at
least three independent experiments performed in duplicate. Statistical
significance was estimated with Student’s t test. A p value of0.05 was
considered significant.
RESULTS
L-Methionine Restriction Induces MAT2A mRNA Levels and
MAT Activity in HepG2 Cells—To evaluate the effect of L-
methionine levels on MAT2A gene expression, HepG2 cells
were cultured for different periods of time in L-methionine-
deficient MEM with 5% fetal calf serum, and MAT2A expres-
sion was assessed by Northern blotting. As shown in Fig. 1A,
MAT2A mRNA levels were dramatically induced by L-methio-
nine restriction in HepG2 cells in a time-dependent fashion.
The intracellular levels of AdoMet in HepG2 cells before L-
methionine restriction (t  0) were 1.2  0.10 nmol/mg of
protein and were reduced to 0.28  0.02 nmol/mg of protein
after 4 h of incubation in L-methionine-deficient medium. The
magnitude of MAT2A mRNA accumulation was also dependent
FIG. 1. L-Methionine depletion induces MAT2A mRNA levels
and MAT activity in HepG2 cells. A, HepG2 cells were incubated in
MEM without L-methionine for different periods of time, and MAT2A
mRNA levels were analyzed by Northern blotting. The expression of
GAPDH and the 18 S rRNA genes was also examined. B, HepG2 cells
were cultured for 24 h in MEM with increasing concentrations of L-
methionine, and the expression of MAT2A, GAPDH, and 18 S rRNA
genes was assessed by Northern blotting. Representative blots of three
different experiments performed in duplicate are shown. C, specific
MAT II activity in HepG2 cells cultured for 24 h in MEM supplemented
with L-methionine (100 M) () or without L-methionine (). Data are
means  S.E. of three experiments performed in triplicates (asterisk
indicates p  0.05).
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on the levels of L-methionine in the culture medium, as ob-
served when HepG2 cells were cultured for 24 h in MEM
supplemented with increasing concentrations of this amino
acid (Fig. 1B). The intracellular levels of AdoMet in cells cul-
tured during 24 h in MEM supplemented with 0, 100, or 1000
M L-methionine were 0.16 0.02, 1.04 0.06, and 1.52 0.01
nmol/mg of protein, respectively. The levels of GAPDH mRNA
and 18 S ribosomal RNA were also measured, and no signifi-
cant changes were observed (Fig. 1, A and B). The induction of
MAT2A gene expression correlated with the up-regulation of
MAT II activity when measured 24 h after culture in L-methi-
onine-restricted MEM (Fig. 1C). The same observations were
made in HuH7 cells (data not shown).
Specificity of MAT2A Response to L-Methionine Deple-
tion—To determine whether the observed up-regulation of
MAT2A mRNA levels was limited to L-methionine restriction in
culture medium, HepG2 cells were grown in complete MEM
(100 M L-methionine) until 70% confluence and subsequently
cultured in KRB buffer for 2 h in the presence of 0 or 100 M
L-methionine. As shown in Fig. 2A, MAT2A gene expression
was induced in methionine-deficient KRB medium, whereas
the addition of L-methionine prevented this response. The ex-
pression of other genes related to AdoMet metabolic pathways,
such as S-adenosylhomocysteine hydrolase and 5-methylthio-
adenosine phosphorylase, was also tested in HepG2 cells under
the above mentioned conditions, and no significant changes
were observed (Fig. 2A).
We next examined the mechanisms through which L-methi-
onine could mediate this acute effect on MAT2A gene expres-
sion. As previously stated, besides its involvement in protein
synthesis, intracellular L-methionine is metabolized into
AdoMet by the action of MAT (Fig. 3 summarizes AdoMet
metabolic pathways). We tested whether AdoMet could mimic
the effect of L-methionine on MAT2A gene expression. For this
purpose, HepG2 cells were cultured in methionine-restricted
MEM for 24 h in the presence of 4 mM AdoMet, and MAT2A
mRNA levels were subsequently analyzed by Northern blot-
ting. Intracellular AdoMet concentrations were measured in
control and AdoMet-treated cells 8 h after the addition of this
compound. These concentrations were 0.20  0.01 and 5.02 
0.2 nmol/mg of protein in control and AdoMet-treated cells,
respectively. As shown in Fig. 2B, the potent induction of
MAT2A gene expression that occurs in the absence of L-methi-
onine (lane 2) was not observed to such an extent when AdoMet
was added to the culture medium (Fig. 2B, compare lanes 2 and
3). However, under the same conditions, the nonmetabolizable
D-isomer of methionine (at 100 M) had no effect on MAT2A
gene expression (Fig. 2B, lane 4). Interestingly, MTA (at 500
M), a product of AdoMet metabolism generated in the poly-
amine biosynthetic pathway and the first molecule in the me-
thionine salvage route (30–32) (Fig. 3), was very effective in
preventing the induction of MAT2A mRNA levels by methio-
nine restriction (Fig. 2B, lane 5). In liver cells, homocysteine
can be remethylated and converted back to methionine through
two alternative pathways that involve the enzyme methionine
synthase or the enzyme betaine-homocysteine methyltrans-
ferase (10, 11) (Fig. 3). Methionine synthase is a cobalamin-de-
pendent enzyme that requires 5-methyltetrahydrofolate to con-
vert homocysteine into methionine (33). We incubated HepG2
cells with homocysteine (200 M), folinic acid (100 M, a pre-
cursor of 5-methyltetrahydrofolate), and cyanocobalamin (15
M) for 24 h in the absence of L-methionine. As shown in Fig.
2B, lane 6, this treatment had no effect on MAT2A mRNA
levels that were strongly induced after 24 h in a methionine-
deficient medium. Similarly, we explored the pathway cata-
lyzed by betaine-homocysteine methyltransferase for the con-
version of homocysteine into methionine by incubating cells
with betaine (2 mM) and homocysteine (200 M) for 24 h in the
absence of the L-methionine addition. This treatment was also
unable to modulate the induction of MAT2A mRNA in response
to L-methionine restriction (Fig. 2B, lane 7).
The induction of MAT2A mRNA elicited by methionine re-
striction could be due either to an increase in transcription of
the gene or to increased mRNA stability. Consequently, we
have measured the effect of L-methionine restriction on the
transcription rate of the MAT2A gene in HepG2 cells by per-
forming nuclear run-on studies. We observed that the tran-
scription rate of the MAT2A gene remained constant at differ-
ent time points after L-methionine withdrawal for up to 4 h;
similarly, the transcription rate of GAPDH was not affected
under this condition (Fig. 4A).
FIG. 2. Specificity of MAT2A gene response to L-methionine
depletion. A, HepG2 cells were grown on L-methionine (100 M)-
supplemented MEM until 70% confluence, and then medium was
changed to KRB buffer for 2 h in the presence () or absence () of
L-methionine (100 M). MAT2A, MTAP, S-adenosylhomocysteine hy-
drolase, GAPDH, and 18 S rRNA gene expression was assessed by
Northern blotting; blots representative of three experiments performed
in duplicate are shown. B, HepG2 cells were cultured for 24 h in the
presence of 100 M L-methionine (lane 1); 0 M L-methionine (lane 2); 4
mM AdoMet (lane 3); 100 M D-methionine (lane 4); 500 M MTA (lane
5); 200 M homocysteine, 100 M folinic acid, and 15 M cyanocobal-
amine (lane 6); or 2 mM betaine and 200 M homocysteine (lane 7).
MAT2A, GAPDH, and 18 S rRNA gene expression were examined by
Northern blotting; blots representative of three experiments performed
in duplicate are shown.
FIG. 3. L-Methionine and AdoMet metabolic pathways. L-Methi-
onine recycling and salvage pathways are presented.
S-Adenosylmethionine Regulates MAT2A mRNA Stability 19887
We next tested whether ongoing transcription or translation
was necessary for the observed induction of MAT2A mRNA
levels in response to L-methionine restriction. For this purpose,
cells were grown in complete MEM until 70% confluence and
then transferred to L-methionine-restricted MEM in the pres-
ence of either actinomycin D (ActD) (5 g/ml) or cycloheximide
(0.1 mM) for 3 h. As shown in Fig. 4, B and C, both treatments
completely abolished the induction of MAT2A mRNA levels.
These observations indicate that both transcription and protein
synthesis are required for the up-regulation of MAT2A gene
expression during L-methionine depletion.
MAT2A mRNA Is Stabilized in L-Methionine-depleted
Cells—Taken together, our data suggest that L-methionine re-
striction increases MAT2A gene expression by stabilizing the
mRNA. To support this hypothesis, we determined MAT2A
mRNA half-life in complete and in L-methionine-depleted
MEM. HepG2 cells growing in complete MEM were incubated
for different periods of time in the presence or absence of ActD
(5 g/ml), and MAT2A mRNA levels were measured by North-
ern blotting. Under this condition, we could estimate that
MAT2A mRNA decayed with a half-life of 100 min in L-
methionine-supplemented medium (Fig. 5A). In order to deter-
mine MAT2A mRNA half-life in L-methionine-restricted me-
dium, cells were cultured in the absence of this amino acid for
4 h and then treated with ActD (5 g/ml) for up to 3 h in the
same medium. As shown in Fig. 5B, the level of MAT2A mRNA
remained constant in L-methionine-depleted cells, suggesting
an mRNA half-life much longer than 3 h.
We wanted to further explore the mechanisms through
which L-methionine could mediate this acute regulation of
MAT2A mRNA levels. We first determined whether AdoMet
and MTA were acting on MAT2A gene expression also at the
level of mRNA stability. For this purpose, HepG2 cells were
incubated for 4 h in L-methionine-deficient MEM, and then
AdoMet (4 mM) or MTA (500 M) was added to the cultures in
the absence or presence of ActD (5 g/ml) and incubations
continued up to 6 h more. Analysis of MAT2A gene expression
under these treatments indicated that both AdoMet and MTA
shared with L-methionine its ability to down-regulate MAT2A
mRNA in the absence of ongoing transcription (Fig. 6). Inter-
estingly, MTA needed to be metabolized through the methio-
nine salvage pathway to exert its effect on MAT2A mRNA
levels, since the concomitant addition of adenine (1 mM), an
inhibitor of MTAP, the first and rate-limiting enzyme in this
pathway (33), completely blocked its effect (Fig. 6). Of particu-
lar relevance is the observation that L-methionine has to be
metabolized and converted into AdoMet to mediate its effect on
MAT2A mRNA levels, as evidenced when L-methionine treat-
ment was performed in the presence of cycloleucine (20 mM), a
competitive inhibitor of MAT activity (34) (Fig. 6). If under
these conditions (treatment with L-methionine and cyclo-
leucine) exogenous AdoMet (4 mM) was added to the cells,
MAT2A mRNA levels were down-regulated (Fig. 6). The addi-
tion of either adenine or cycloleucine to L-methionine-starved
cells had no effect on MAT2A mRNA levels (data not shown).
As previously mentioned, an essential role of L-methionine,
through its conversion into AdoMet, is to provide the cell with
the necessary activated methyl groups for a vast number of
transmethylation reactions. Hence, it was important to know if
a transmethylation reaction(s) could be involved in the regula-
tion of MAT2A mRNA levels. For this purpose, L-methionine-
deprived cells were treated with L-methionine in the presence
of the adenosine analog 3-deazaadenosine (C3-Ado) (30 M, 30
min prior to L-methionine addition) (37). C3-Ado is an inhibitor
of S-adenosylhomocysteine hydrolase and leads to a significant
increase in the intracellular levels of AdoHcy; additionally, it
can be converted into the more stable 3-deaza-derivative of
AdoHcy (S-3-deaza-adenosylhomocysteine (C3-AdoHcy)) (37).
AdoHcy and C3-AdoHcy are strong inhibitors of methylation
reactions (14, 37). We observed that the effect of L-methionine
was preserved in the presence of C3-Ado (Fig. 6), suggesting
that methylation reactions were not involved in the regulation
of MAT2A gene expression by this amino acid.
FIG. 4. Effect of L-methionine levels on MAT2A gene transcrip-
tion in HepG2 cells. A, nuclear run-on assay of MAT2A gene tran-
scription performed in nuclei isolated from HepG2 cells maintained for
either 2 or 4 h in 0 or 100 M L-methionine. Labeled RNAs were
synthesized by isolated nuclei and hybridized against MAT2A, GAPDH,
and 18 S rRNA cDNAs on slot blots (pUC18 plasmid DNA was used for
background control). Experiments were performed two times in dupli-
cate, and a representative blot is shown. B, Northern blot analysis of
MAT2A mRNA levels from HepG2 cells kept in MEM with 100 M
L-methionine (lane 1), 0 M L-methionine for 3 h (lane 2), or 0 M
L-methionine plus 5 g/ml ActD for 3 h. C, Northern blot analysis of
MAT2A mRNA levels from HepG2 cells kept in MEM with 100 M
L-methionine (lane 1), 0 M L-methionine for 3 h (lane 2), or 0 M
L-methionine plus 0.1 mM cycloheximide for 3 h. Analysis was per-
formed also with an 18 S rRNA cDNA probe for loading control. Rep-
resentative blots from three experiments performed in duplicate are
shown.
FIG. 5. Effect of L-methionine depletion on the half-life of
MAT2A mRNA in HepG2 cells. A, quantitation of MAT2A mRNA
levels in HepG2 cells kept in MEM supplemented with 100 M L-
methionine in the absence (closed circles) or presence (closed triangles)
of 5 g/ml ActD for different periods of time. B, quantitation of MAT2A
mRNA levels in HepG2 cells that were kept for 4 h in L-methionine-
depleted MEM and then (time 0) further treated for up to 3 h in the
absence (closed circles) or presence (closed triangles) of 5 g/ml ActD.
Data are means  S.E. of three experiments performed in duplicate
(asterisk indicates p  0.05 with respect controls without ActD). Values
were normalized to 18 S rRNA levels.
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DISCUSSION
In this work, we have provided evidence for the acute regu-
lation of MAT2A gene expression in response to the availability
of L-methionine. Incubation of human hepatoma HepG2 cells
(and HuH7 cells; not shown) in medium restricted in this
amino acid resulted in the rapid induction of MAT2A mRNA
levels in a time- and concentration-dependent manner. A par-
allel increase in MAT activity was observed in cells cultured
under reduced L-methionine availability, suggesting that
translation of MAT2A mRNA was taking place even in the
presence of limiting amounts of L-methionine. This observation
is in agreement with other reports showing the induction of
specific proteins under limited availability of L-methionine (38,
39). MAT2A gene response seemed to be mainly due to changes
in L-methionine levels and not to fluctuations in other amino
acids or nutrients. This may be inferred by our experiments in
which HepG2 cells were incubated in KRB buffer and induction
of MAT2A gene expression was modulated by the sole addition
of L-methionine.
As mentioned previously, besides its role in protein synthe-
sis, L-methionine enters a metabolic pathway in which it is
converted, together with ATP, into AdoMet, the main methyl
donor compound in the cell. It was important to know if the
observed response of MAT2A gene to fluctuations in L-methio-
nine levels could be related to this metabolic pathway. We
observed that AdoMet addition to L-methionine-starved cul-
tures was effective in down-regulating the expression of
MAT2A gene. This observation, together with the finding that
the nonmetabolizable D-isomer of methionine had no effect on
MAT2A mRNA levels, provided the first evidence supporting
the concept that L-methionine mediates its effect on MAT2A
gene expression through its conversion into AdoMet. We also
tested the effect of other molecules that are subsequent meta-
bolic products of L-methionine and AdoMet, such as homocys-
teine and MTA. Homocysteine treatment had no effect on
MAT2A mRNA levels, suggesting that this metabolite was not
involved in the cellular signaling of L-methionine limitation.
Homocysteine can serve as a precursor of L-methionine in all
cells; however, transformed cells, including hepatoma cells, are
unable to grow if homocysteine is used in place of methionine in
culture medium (13, 40, 41). Our present data further support
this notion. With regard to MTA, a product of AdoMet metab-
olism in the polyamine biosynthetic pathway and a precursor of
L-methionine in the so-called methionine salvage pathway, we
observed that it was able to modulate MAT2A mRNA levels in
L-methionine-starved cultures. As we later observed, MTA ef-
fect was dependent on its metabolism through the methionine
salvage pathway and therefore probably due to its ultimate
conversion into this amino acid and subsequently into AdoMet.
Adenine, a product of MTA metabolism and an inhibitor of
MTAP, the first and rate-limiting enzyme in the methionine
salvage pathway (30–32, 35), blocked MTA effect. Methionine
dependence of tumor cells has been associated with defects in
MTAP expression leading to the suppression of this salvage
pathway (13, 41, 42); however, this is not the case for HepG2,
where we found that MTAP expression was normal (data not
shown). Additionally, these data attest to the importance of the
methionine salvage pathway in methionine conservation under
limited supply of this amino acid and further support the
relevance of this metabolic route as a target in antineoplastic
therapy.
We have provided evidence showing that MAT2A gene tran-
scription remained constant during L-methionine starvation at
least up to 4 h after the removal of this amino acid from the
culture medium. These data suggested that the potent effect of
L-methionine on MAT2A gene expression might take place at
the post-transcriptional level. In the regulation of gene expres-
sion by amino acids, both types of mechanisms, namely the
regulation of gene transcription and of mRNA stability, have
been described. For instance, transcription of the asparagine
synthetase gene and the stability of the high affinity cationic
amino acid transporter-1 mRNA are known to be modulated by
amino acid starvation (43, 44). In the case of certain genes,
such as cationic amino acid transporter-1, changes in its mRNA
turnover rate alone account for the dramatic induction on the
expression of this gene in amino acid-depleted medium (44, 46).
Because the MAT2A gene transcription rate was not signif-
icantly altered by L-methionine starvation, we measured
MAT2A mRNA half-life in L-methionine-fed and -starved cul-
tures. We observed a significant increase in MAT2A mRNA
half-life in response to L-methionine starvation. Interestingly,
this effect was completely dependent on de novo protein syn-
thesis. This observation suggests that a protein factor(s) may
be synthesized that binds and stabilizes MAT2A mRNA when
cellular L-methionine levels are reduced. This kind of mecha-
nism has been reported for the regulation of mRNAs encoding
proteins such as transferrin receptor (45), the cationic amino
acid transporter-1 (46), and others (47).
Once we established that MAT2A gene expression was reg-
ulated by L-methionine at the level of mRNA turnover, we
confirmed that the observed effects of AdoMet and MTA on
MAT2A steady state mRNA levels were also mediated at this
same level. In these experiments, it was also clearly estab-
lished that L-methionine per se was not sufficient to convey the
cellular signal(s) that modulated MAT2A mRNA turnover.
Conversion of L-methionine into AdoMet was absolutely neces-
sary, given the fact that cycloleucine, a competitive inhibitor of
MAT II activity (34), completely abolished L-methionine action.
In line with this is the observation that when exogenous
AdoMet was added, the blockade imposed by cycloleucine on
L-methionine effect was overcome. Taken together, these find-
ings provide an explanation for our previous observations made
in MAT1A knockout mice. These animals display dramatically
elevated levels of circulating L-methionine (around 8-fold in-
crease compared with wild type mice), and at the same time the
FIG. 6. Mechanism of L-methionine regulation of MAT2A
mRNA stability. MAT2A mRNA levels were determined by Northern
blotting in HepG2 cells that were kept in L-methionine-depleted MEM
for 4 h and then further incubated for 3 or 6 h more in the absence or
presence of 5 g/ml ActD and the indicated treatments: without L-
methionine, 100 M L-methionine, 4 mM AdoMet, 500 M MTA, 500 M
MTA plus 1 mM adenine, 100 M L-methionine plus 30 M C3-Ado, 100
M L-methionine plus 20 mM cycloleucine, 100 M L-methionine, and 4
mM AdoMet plus 20 mM cycloleucine. Representative blots of three
experiments performed in duplicate are shown.
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expression of the MAT2A gene is induced in their liver (21).
These seemingly contradictory observations may be explained
by the fact that the hepatic concentration of AdoMet in these
knockout mice is reduced to about 25% of that found in wild
type animals (21).
Another interesting finding was the observation that treat-
ment with C3-Ado, a compound that increases the intracellular
concentration of AdoHcy, and C3-AdoHcy, two potent inhibitors
of methylation reactions, did not interfere with the effect of
L-methionine on MAT2A mRNA levels. This finding suggests
that a methylation reaction is not involved in the effect of
L-methionine (and consequently of AdoMet) on MAT2A gene
expression, although we cannot exclude a methyl transfer re-
action that would be resistant to AdoHcy or C3-AdoHcy inhibi-
tion. We have previously described that AdoMet is able to
induce the transcription of the MAT1A gene in cultured rat
hepatocytes (24, 25) and that in this effect a methylation reac-
tion is probably involved (24). Now we report on a novel effect
of AdoMet on gene expression that occurs at the postranscrip-
tional level and in which a different mechanism of action is
seemingly involved. An alternative mode of action for AdoMet
could be its direct binding to a cellular target structure. Such
interaction of AdoMet is known to occur in eukaryotic cells, and
the best characterized target is the enzyme cystathionine
-synthase, which is allosterically regulated by AdoMet bind-
ing to a specific domain termed the cystathionine -synthase
domain (49). Interestingly, this cystathionine -synthase do-
main is a widespread structure that was originally described in
archaebacteria and is well conserved throughout evolution (50).
Given the central role played by AdoMet in cellular metab-
olism, the sharp induction in MAT2A gene expression in re-
sponse to reduced L-methionine and AdoMet availability could
be regarded as an adaptive mechanism of the cell aimed at
preserving the intracellular levels of AdoMet. As we have
shown, this is a finely tuned response, and we can envision
different potential explanations for this to be so. In the first
place, for each AdoMet molecule synthesized, one ATP mole-
cule and one L-methionine molecule are consumed at the ex-
pense of the homeostasis of cellular energetics and protein
synthesis (10, 11). Additionally, recent observations suggest
that AdoMet plays a role in the cell that transcends its purely
metabolic function as a methyl donor and metabolic interme-
diate (reviewed in Ref. 26). Changes in AdoMet levels modulate
proliferation, apoptosis, and differentiation, so its synthesis
needs to be carefully controlled. In this regard, the inhibitory
effect of AdoMet on MAT II activity has been well characterized
(12, 13, 48). Our present observations represent a novel action
of AdoMet in the regulation of cellular physiology, this time
modulating its own production also through the regulation of
MAT2A mRNA stability.
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